After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead has said it has begun two phase 3 trials of its potential COVID-19 coronavirus antiviral remdesivir in adults affected by the disease, expanding ongoing research in the US and China. The ...

The EU drugs regulator says Gilead Sciences’ antiviral drug remdesivir should be made available for people seriously ill with COVID-19, despite limited data on its efficacy. The EMA’s human ...

Monkeys infected with Ebola can be cured with a pill, according to a new study out Friday that could pave the way for more ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

“Gilead is continuing to innovate in our work ... is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Gilead achieved a breakthrough in HIV treatment with its Lenacapavir drug, which had 100% in Purpose 1 and 99.9% in Purpose 2 studies in HIV prevention. Lenacapavir, an antiviral drug sold under ...

Emerging data suggest that antiviral therapy in the third trimester ... Pan has received research grants from Gilead, Bristol Myers Squibb, Novartis, and Roche. He also serves as a consultant ...

While most antivirals act on just one stage of viral ... ongoing and planned early and late-stage clinical studies in Gilead’s HIV prevention and treatment research program.